While nature provides a large library of natural compounds optimized for their activity, these compounds are not necessarily suitable for clinical development in their native form. In fact, most natural drugs do fail during development due to adverse medicinal chemistry features. The M-tech platform allows OxAG to identify these problems early in development and avoid costly late-stage failures. Together with the outstanding expertise of the OxAG team, the M-biotic platform will allow OxAG to reduce the failure rate of the drug development program while at the same time laying the foundation for a structure-activity program early on in the development process.